https://www.dailypharm.com/user/news/344038
[데일리팜]"키스칼리, 유방암 재발 예방 가치 재확인…접근성 높여야"
키스칼리의 6년 장기 추적 결과가 공개되면서 조기 유방암 환자의 재발 예방을 위한 보조요법의 임상적 가치가 다시 주목받고 있다. 기존에 확인된 재발 위험 감소 효과에 이어 전체생존율(OS)
www.dailypharm.com
The 6-year long-term follow-up results for Kisqali were disclosed, reconfirming the clinical value of adjuvant therapy for preventing recurrence in early breast cancer patients. As evidence supporting overall survival improvements is added on top of its existing recurrence risk reduction effect, the need to expand treatment accessibility in South Korea is highlighted. The findings present the potential for long-term survival benefits of Kisqali combination therapy and are expected to significantly influence domestic health insurance reimbursement discussions.
댓글